CellaVision Past Earnings Performance
Past criteria checks 4/6
CellaVision hat die Erträge mit einer durchschnittlichen jährlichen Rate von 5.8% gesteigert, während die Branche Medical Equipment die Erträge growing mit 5.8% jährlich steigerte. Die Einnahmen sind growing mit einer durchschnittlichen Rate von 10.9% pro Jahr gestiegen. CellaVision Die Eigenkapitalrendite des Unternehmens beträgt 18.2%, und die Nettomargen liegen bei 19.2%.
Key information
5.8%
Earnings growth rate
5.8%
EPS growth rate
Medical Equipment Industry Growth | 6.2% |
Revenue growth rate | 10.9% |
Return on equity | 18.2% |
Net Margin | 19.2% |
Next Earnings Update | 25 Apr 2024 |
Recent past performance updates
Recent updates
CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25
Mar 28CellaVision's (STO:CEVI) Dividend Will Be SEK2.25
Mar 14CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25
Feb 29After Leaping 28% CellaVision AB (publ) (STO:CEVI) Shares Are Not Flying Under The Radar
Feb 16CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25
Feb 12Earnings Beat: CellaVision AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Feb 10CellaVision's (STO:CEVI) Returns On Capital Not Reflecting Well On The Business
Dec 13Is Now An Opportune Moment To Examine CellaVision AB (publ) (STO:CEVI)?
Sep 14Calculating The Intrinsic Value Of CellaVision AB (publ) (STO:CEVI)
Aug 22CellaVision (STO:CEVI) Is Reinvesting At Lower Rates Of Return
Jun 17CellaVision's (STO:CEVI) Upcoming Dividend Will Be Larger Than Last Year's
May 07Estimating The Fair Value Of CellaVision AB (publ) (STO:CEVI)
Apr 19CellaVision (STO:CEVI) Is Increasing Its Dividend To SEK2.25
Apr 05CellaVision (STO:CEVI) Is Paying Out A Larger Dividend Than Last Year
Mar 04CellaVision AB (publ) (STO:CEVI) Analysts Are More Bearish Than They Used To Be
Feb 11Is CellaVision (STO:CEVI) A Risky Investment?
Jan 13Is CellaVision AB (publ) (STO:CEVI) Potentially Undervalued?
Dec 13CellaVision (STO:CEVI) Seems To Use Debt Rather Sparingly
Sep 23CellaVision (STO:CEVI) May Have Issues Allocating Its Capital
Aug 16Calculating The Intrinsic Value Of CellaVision AB (publ) (STO:CEVI)
Aug 02We Ran A Stock Scan For Earnings Growth And CellaVision (STO:CEVI) Passed With Ease
Jun 27What Is CellaVision AB (publ)'s (STO:CEVI) Share Price Doing?
May 31CellaVision (STO:CEVI) Could Easily Take On More Debt
Apr 28Calculating The Intrinsic Value Of CellaVision AB (publ) (STO:CEVI)
Apr 07Some Investors May Be Worried About CellaVision's (STO:CEVI) Returns On Capital
Mar 26If You Like EPS Growth Then Check Out CellaVision (STO:CEVI) Before It's Too Late
Mar 08Is Now An Opportune Moment To Examine CellaVision AB (publ) (STO:CEVI)?
Feb 17Is CellaVision AB (publ) (STO:CEVI) Worth kr320 Based On Its Intrinsic Value?
Dec 25Here's Why I Think CellaVision (STO:CEVI) Is An Interesting Stock
Nov 23Returns On Capital Signal Tricky Times Ahead For CellaVision (STO:CEVI)
Sep 28These 4 Measures Indicate That CellaVision (STO:CEVI) Is Using Debt Reasonably Well
Sep 13Revenue & Expenses BreakdownBeta
How CellaVision makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 677 | 130 | 213 | 83 |
30 Sep 23 | 629 | 112 | 202 | 83 |
30 Jun 23 | 602 | 97 | 196 | 91 |
31 Mar 23 | 616 | 99 | 196 | 91 |
31 Dec 22 | 639 | 118 | 191 | 89 |
30 Sep 22 | 651 | 126 | 194 | 86 |
30 Jun 22 | 642 | 142 | 186 | 72 |
31 Mar 22 | 594 | 135 | 174 | 67 |
31 Dec 21 | 566 | 125 | 165 | 64 |
30 Sep 21 | 532 | 114 | 160 | 61 |
30 Jun 21 | 488 | 101 | 150 | 54 |
31 Mar 21 | 471 | 98 | 147 | 52 |
31 Dec 20 | 471 | 89 | 152 | 51 |
30 Sep 20 | 490 | 85 | 159 | 54 |
30 Jun 20 | 498 | 89 | 165 | 59 |
31 Mar 20 | 492 | 92 | 163 | 60 |
31 Dec 19 | 462 | 99 | 150 | 56 |
30 Sep 19 | 423 | 104 | 135 | 53 |
30 Jun 19 | 412 | 104 | 131 | 48 |
31 Mar 19 | 391 | 97 | 124 | 43 |
31 Dec 18 | 365 | 89 | 120 | 39 |
30 Sep 18 | 330 | 76 | 114 | 33 |
30 Jun 18 | 307 | 67 | 109 | 30 |
31 Mar 18 | 294 | 63 | 106 | 27 |
31 Dec 17 | 309 | 70 | 106 | 27 |
30 Sep 17 | 306 | 70 | 101 | 28 |
30 Jun 17 | 313 | 78 | 97 | 28 |
31 Mar 17 | 300 | 75 | 92 | 30 |
31 Dec 16 | 265 | 60 | 86 | 29 |
30 Sep 16 | 254 | 57 | 85 | 29 |
30 Jun 16 | 260 | 66 | 82 | 27 |
31 Mar 16 | 246 | 55 | 82 | 28 |
31 Dec 15 | 239 | 53 | 82 | 27 |
30 Sep 15 | 250 | 49 | 84 | 29 |
30 Jun 15 | 223 | 30 | 82 | 28 |
31 Mar 15 | 226 | 34 | 83 | 25 |
31 Dec 14 | 217 | 31 | 80 | 23 |
30 Sep 14 | 209 | 33 | 73 | 19 |
30 Jun 14 | 207 | 36 | 70 | 17 |
31 Mar 14 | 189 | 26 | 67 | 18 |
31 Dec 13 | 180 | 19 | 66 | 21 |
30 Sep 13 | 165 | 3 | 67 | 21 |
30 Jun 13 | 156 | -1 | 68 | 22 |
Qualität der Erträge: CEVI hat hohe Qualitätseinkünfte.
Wachsende Gewinnspanne: CEVIDie aktuellen Gewinnspannen (19.2%) sind höher als im letzten Jahr (18.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Ergebnisentwicklung: CEVIIn den letzten 5 Jahren sind die Gewinne von 5.8% jährlich gestiegen.
Beschleunigtes Wachstum: CEVIDas Gewinnwachstum des Unternehmens im letzten Jahr (10.1%) übertrifft seinen 5-Jahres-Durchschnitt (5.8% pro Jahr).
Erträge im Vergleich zur Industrie: CEVI Das Gewinnwachstum im vergangenen Jahr (10.1%) übertraf nicht die Entwicklung der Branche Medical Equipment 62.7% .
Return on Equity
Hohe Eigenkapitalrendite: CEVIDie Eigenkapitalrendite des Unternehmens (18.2%) wird als niedrig angesehen.